Nymox Announces Appointment of Scientific Consultants, Dr. Thomas Hudson and Dr. Joe Dylewski.Health/Medical Writers MAYWOOD, N.J.--(BW HealthWire)--March 19, 2001 Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NYMX NYMX New York Mercantile Exchange ) is pleased to announce the appointment of Dr. Thomas J. Hudson Thomas James Hudson, M.D., (born June 12, 1961) is a Canadian genome scientist noted for his leading role in the generation of physical maps of the human and mouse genomes and also his role in the International HapMap Project whose goal is to develop a haplotype map of the human , M.D., and Dr. Joe Dylewski, M.D. as scientific consultants. Dr. Thomas Hudson is an internationally renowned researcher in genomics. He is the Assistant Director of the Whitehead Institute/MIT Center for Genome Research and led the effort there to map and sequence the human genome. The Whitehead Institute's Center for Genome Research is the largest public sequencing center in the world and part of the international consortium of 16 laboratories that comprise the Human Genome Project. Dr. Hudson is also the founder and Director of the Montreal Genome Centre at the McGill University Health Centre The McGill University Health Centre (MUHC) (in French, Centre universitaire de santé McGill) is a network of five teaching hospitals in Montreal, Quebec, Canada, all of which are affiliated with McGill University. Research Institute. He has been a leader in the development and applications of robotic systems and DNA-chip based methodologies for genome research, including the use of DNA-chip technology to characterize breast and ovarian cancer. His research interests also include human genetic diseases with a focus on the dissection of complex genetic diseases and the search for genes predisposing to lupus, inflammatory bowel disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. , coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. , asthma and diabetes. As well as doing research, Dr. Hudson teaches at the Department of Medicine and the Department of Human Genetics at McGill University and is a practising physician at the Montreal General Hospital The Montreal General Hospital is a hospital in Montreal, Canada, first established on May 1, 1819 and an early teaching hospital. The hospital has moved several times in the past, and is currently situated on Mount Royal, at the intersection of Cedar Avenue and Cote des Neiges . He has been the recipient of many awards, including the Clinician Scientist Award from the Medical Research Council of Canada, and been a member of many public sector advisory committees, include being the current Chair of the Scientific Advisory Committee of Genome Quebec and a member of the Canadian Biotechnology Advisory Committee. Dr. Joe Dylewski is the Director of Microbiology, Head of the Division of Infectious Disease and Chief of Laboratories at St. Mary's Hospital in Montreal Quebec. Dr. Dylewski specializes in microbiology and infectious diseases and brings to Nymox a wealth of clinical and research experience in this area. He has published extensively in the medical literature. He is an Associate Professor of Medicine at McGill University and a Fellow of the Royal College of Physicians The Royal College of Physicians of London was the first medical institution in England to receive a Royal Charter. It was founded in 1518 and is one of the most active of all medical professional organisations. (Canada) in both Medical Microbiology and Internal Medicine. He is also a member of the American Society of Microbiology and a Diplomate dip·lo·mate n. One who has received a diploma, especially a physician certified as a specialist by a board of examiners. diplomate (dip´l with the American Board of Internal Medicine The American Board of Internal Medicine (ABIM) is a non-profit, independent physician organization in the U.S. that certifies physicians who practice in internal medicine and its sub-specialties. . Nymox Pharmaceutical Corporation pioneers in the research and development of products for the diagnosis and treatment of Alzheimer's disease, an affliction of more than 15 million people around the world. Nymox offers the world's only accurate, non-invasive test to aid in the diagnosis of the disease, and is developing proprietary spheron-based drug therapies that could lead to effective treatment of Alzheimer's disease. Nymox markets NicAlert(TM), a test that uses urine or saliva to determine whether a person is using tobacco products. Nymox is developing a new class of antibacterial agents for the treatment of urinary tract and other bacterial infections in humans which have proved highly resistant to conventional antibiotic treatments and for the treatment of E. coli 0157:H7 bacterial contamination in hamburger meat and other food and drink products. Under development are a potential saliva-based cholesterol test and a test for osteoporosis. Nymox Pharmaceutical Corporation has facilities in Montreal and Maywood, NJ. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion